CLS Q4 2022: Important 2023 ahead - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

CLS Q4 2022: Important 2023 ahead - Redeye

{newsItem.title}

Redeye provides an update in relation to CLS’ Q4 2022 report. The report did not include any major surprises in our view; however, we expect quarterly reports to become more interesting as we expect sales to ramp up during 2023. We have chosen not to make any changes in our future estimates; however, we update the current cash position and our capital raising assumptions, which results in a new fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/884576/cls-q4-2022-important-2023-ahead?utm_source=finwire&utm_medium=RSS

Nyheter om Clinical Laserthermia

Läses av andra just nu

Om aktien Clinical Laserthermia

Senaste nytt